Abstract. Genome-wide association studies identified that a series of genes, including solute carrier family (SLC) 2 member 9 (SLC2A9), SLC 22 member 12 (SLC22A12) and ATP-binding cassette sub-family G member 2 (ABCG2) polymorphisms were associated with serum uric acid (SUA) levels in the present study. High incidence rates of hyperuricemia were reported in the Chinese population of the southeast coastal region; however, no evidence has confirmed the genetic association with SUA levels in this region. The present study aimed to investigate the association between uric acid levels and hyperuricemia, and genotypes of the Chinese population of the southeast coastal region. In the present study, a total of 1,056 healthy patients attending routine checkups were employed to investigate the incidence of hyperuricemia; 300 subjects were then randomly selected from the 1,056 patients for the identification of genetic polymorphisms of SLC2A9rs11722228, SLC22A12rs893006 and ABCG2rs2231142 via high-resolution melting. The present study reported that the incidence rate of hyperuricemia was 32.6% (42.5% in males and 22.7% in females, respectively). The prevalence of ABCG2rs2231142 polymorphisms (CC, CA and AA) was 44.4, 44.8 and 11.8%, respectively; SLC2A9rs11722228 polymorphisms (CC, CT and TT) were reported to be 49.3, 40.3 and 10.3%, respectively. Additionally, SLC22A12rs893006 polymorphisms (CC, CT and TT) were determined to be 57.2, 38.7 and 4.1%, respectively. The SUA levels were observed to be statistically different among each investigated genotype of ABCG2rs2231142 (P=0.047). The A allele was significantly associated with an increased risk of hyperuricemia (odds ratio=2.405 and 1.133 for CA and AA, respectively). The present study reported that high incidence rates of hyperuricemia in the Chinese population of the southeast coastal region may be closely associated with the variants of ABCG2rs2231142. Whether polymorphisms of SLC2A9rs11722228 and SLC22A12rs893006 are involved in hyperuricemia require further investigation.

Introduction

Uric acid (UA) is the final metabolic product of purine metabolism in humans (1). A total of two-thirds of the uric acid within the human body is normally excreted via the kidneys; the remaining third is excreted via the intestinal tract (1). Elevated serum uric acid (SUA) levels have been strongly associated with myocardial syndrome, diabetes and cardiovascular disease, and an increased risk of mortality in mature individuals (≥18 years old) (2).

SUA levels are governed by the balance between purine absorbed from the diet and that excreted via the kidneys. In >90% of cases, elevated SUA levels result from impaired renal excretion (1,3,4). Genetic factors may affect the critical reabsorption process of UA in the proximal renal tube, which may contribute to 40-70% of the overall SUA levels (5,6). Previous genome-wide association studies (GWAS) have identified an association between multiple gene loci, including solute carrier family (SLC) 2 member 9 (SLC2A9)/glucose transporter 9 (GLUT9), ATP-binding cassette sub-family G member 2 (ABCG2), SLC 22 member 12 [SLC22A12/urate transporter 1 (URAT1)], SLC 22 member 11 and SLC 16 member 9 and SUA levels in the European population (4,7). It
has been previously indicated that SUA levels are influenced by gene-environment interactions (8). Studies have investigated the association between SUA levels and genotype in Japanese and Korean populations (9-11); however, further investigation of the Chinese population is required (12).

It has been reported that the Chinese population of the southeast coastal region have a diet rich in seafood, which may be associated with the onset of hyperuricemia (13). However, strict control of diet alone is insufficient to reduce the levels of SUA within this region (14,15), indicating that dysregulation of UA excretion may be a principal factor associated with hyperuricemia; polymorphisms in urate-anion exchanger genes may serve an important role in this process. At present, no epidemiological investigations into the association between hyperuricemia and genotype have been performed in this region. The present study aimed to investigate the epidemiology of hyperuricemia in the Chinese population of the southeast coastal region; a total of three single nucleotide polymorphism (SNPs) were selected (SLC2A9 rs11722228, SLC22A12 rs893006 and ABCG2 rs2231142) to examine their associations with SUA levels.

High-resolution melting (HRM) is a novel molecular approach that was originally developed for SNP genotyping and detection (16). This method employs a single-step closed tube, facilitating an economical procedure for rapid, specific and sensitive detection. In the present study, an HRM assay was generated to detect three functional SNPs; the genetic association of these SNPs with SUA levels was also examined.

Materials and methods

Subjects and data collection. A total of 1,056 healthy patients attending routine checkups (543 males and 514 females; aged 20-50 years old) at the Medical Examination Center of The First Affiliated Hospital of Shantou University Medical College (Shantou, China) were enrolled in the present study between January 2015 and December 2015. The inclusion criteria were as follows: Serum creatinine levels ≤133 µmol/l for males and ≤108 µmol/l for females. Hyperuricemia was defined as SUA levels exceeding 420 µmol/l in males and 360 µmol/l in females. The characteristics of participants, including age, sex, body mass index, total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, glucose levels and place of origin are reported (Table I). A total of 300 subjects were randomly selected from the 1,056 patients for polymerase chain reaction (PCR)-HRM genotyping analysis. All participants provided written informed consent for enrolment into the present study and for genotype analysis. The present study was approved by the Ethics Committee of The First Affiliated Hospital of Shantou University Medical College.

Measurement of SUA levels. Venous blood samples (3 ml) were drawn from the individuals following an overnight fast. SUA levels were measured using a uricase-peroxidase method (17) via an automated system (Beckman AU5800; Beckman Coulter, Inc., Brea, CA, USA).

PCR-HRM. Genomic DNA was extracted from venous blood samples (3 ml) using a Lab-Aid® 824 DNA Extraction kit (Xiamen Zeesan Biotech, Co., Ltd., Xiamen China) according to the manufacturer's protocol. Oligonucleotide primers were designed using primer premier5 software (http://macdownload.informer.com/advice/Primer_Premier_5.html) and synthesized by Sangon Biotech Co., Ltd. (Shanghai, China) (Table II). Each PCR employed 30 ng DNA, 2X HRM PCR Master Mix (Qiagen, Inc., Valencia, CA, USA) and 10 µM primer mix; the solution was made up to 25 µl with RNase-Free water. PCR was performed on a LightCycler 480 system (Roche Diagnostics, Basel, Switzerland). All reactions were conducted under the following conditions: 95°C for 5 min (1 cycle), 35 cycles of 95°C for 10 sec and 55°C for 30 sec. The optimum annealing temperature and amplified fragment size for each SNP was modified according to the primer design (Table II).

Following PCR, the amplified fragments were confirmed by electrophoresis using 1.5% (w/v) agarose gels, which were subsequently visualized using 0.5 µg/ml ethidium bromide. Following this, a total of 50 DNA samples were randomly selected from 300 samples for genotype analysis by sequencing (as described below). Analysis of the wild-type, heterozygous and homozygous type for each SNP was conducted, which was compared with the 50 DNA samples of known genotype represented the control in the following HRM analysis steps.

DNA samples as mentioned previously as well as the unknown samples were examined via PCR-HRM curves mixed with known genotype samples (wild-type, heterozygous and homozygous). PCR thermocycling and HRM were performed on a LightCycler 480 (Roche Diagnostics). All reactions were detected under the following conditions: 95°C for 5 min (1 cycle), 35 cycles of 95°C for 10 sec and 55°C for 30 sec, and a melting stage from 65-95°C, which was reported at intervals of 0.02°C/sec. HRM curves were analyzed using Roche 480 2.0 software (Roche Diagnostics).

Sequencing. To further verify the results of PCR-HRM genotyping, 50 DNA samples were randomly selected from the total 300 samples and examined via sequencing. Novel primers (Table II) were designed for the sequencing of gene regions containing SNPs that yielded products with lengths >200 bp. DNA sequencing was performed by Sangon Biotech Co., Ltd.

Bioinformatics analysis. Linkage disequilibrium analyses were performed using Haploview 4.2 software (www.broad-institute.org/haploview/downloads). R²>0.8 was considered to represent complete linkage disequilibrium. DNAMAN (version 8.0; Lynnon BioSoft, Vaudreuil, QC, Canada) was used for DNA sequence alignment between the National Center for Biotechnology Information database (http://www.ncbi.nlm.nih.gov) and the sequencing results generated by the present study.

Statistical analysis. The Hardy-Weinberg equilibrium of the three SNPs was examined with a χ² test. Analysis of variance was used to evaluate the difference in SUA levels in each genotype followed by the Least Significant Difference post-hoc test. The odds ratio (OR) and 95% confidenceinterval (CI) were calculated by a binary logistic model to identify factors that may influence the concentration of SUA. All statistical analyses were performed using SPSS 20.0
Results

Epidemiological analysis. The epidemiological investigation of the Chinese population in the southeast coastal region revealed that the mean levels of SUA were 365.27±116.85 µmol/l (410.25±110.36 µmol/l for males; 320.39±102.12 µmol/l for females; data not shown). Based on the diagnostic criteria, a mean of 32.6% subjects were considered to have hyperuricemia (42.5% for males; 22.7% for females). The characteristics of patients are presented in Table I.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Hyperuricemia&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Normal serum uric acid</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients (%)</td>
<td>Male: 231 (42.5)</td>
<td>Female: 117 (22.7)</td>
</tr>
<tr>
<td>Age, years</td>
<td>37.02±12.56</td>
<td>37.01±12.86</td>
</tr>
<tr>
<td>Body mass index</td>
<td>21.77±0.96</td>
<td>22.01±1.91</td>
</tr>
<tr>
<td>Creatinine</td>
<td>110.95±15.96</td>
<td>95.33±9.86</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>3.02±1.16</td>
<td>1.68±0.91</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>7.33±3.82</td>
<td>5.92±1.27</td>
</tr>
<tr>
<td>Low density lipoprotein</td>
<td>5.72±2.21</td>
<td>2.97±3.64</td>
</tr>
<tr>
<td>High density lipoprotein</td>
<td>1.21±0.33</td>
<td>1.11±0.51</td>
</tr>
<tr>
<td>Glucose</td>
<td>7.56±2.21</td>
<td>7.02±3.31</td>
</tr>
<tr>
<td>Serum uric acid, µmol/l</td>
<td>494.01</td>
<td>421.24</td>
</tr>
</tbody>
</table>

<sup>a</sup>Hyperuricemia constituted uric acid levels: Male, ≥420 µmol/l; female, ≥360 µmol/l. Data are presented as the mean ± standard deviation.

Table II. Primer sequences.

A. PCR-HRM

<table>
<thead>
<tr>
<th>SNP</th>
<th>SNP Allele</th>
<th>Sequence (5’→3’)</th>
<th>Size, bp</th>
<th>Temperature</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLC2A9 rs11722228</td>
<td>C/T</td>
<td>F: TGAGTGCCAGAGCTGAGATCG R: TCTCACCCAGAGTTAGGCAGAG</td>
<td>73</td>
<td>55°C</td>
</tr>
<tr>
<td>SLC22A12 rs893006</td>
<td>C/A</td>
<td>F: CCACAATCTTCAGGGAGGAGA R: TGCTACCTGTACCACACTGC</td>
<td>146</td>
<td>60°C</td>
</tr>
<tr>
<td>ABCG2 rs2231142</td>
<td>C/A</td>
<td>F: TGTCCTCATTTAAATGCTATTTGCCT R: GTGCAAGGCGAAGAGCTG</td>
<td>100</td>
<td>61°C</td>
</tr>
</tbody>
</table>

B. Genotyping

<table>
<thead>
<tr>
<th>SNP</th>
<th>SNP Allele</th>
<th>Sequence (5’→3’)</th>
<th>Size, bp</th>
<th>Temperature</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLC2A9 rs11722228</td>
<td>C/T</td>
<td>F: TGTGGCTGGGTCTAGCATCT R: ATTGTGCTTGGGGCTGTGGAT</td>
<td>623</td>
<td>59°C</td>
</tr>
<tr>
<td>SLC22A12 rs893006</td>
<td>C/A</td>
<td>F: GACAGGAAGGCCATGTGGTAT R: CTCCCTCTCTGAGACCTCTTCT</td>
<td>713</td>
<td>60°C</td>
</tr>
<tr>
<td>ABCG2 rs2231142</td>
<td>C/A</td>
<td>F: GGCCTTTGTAAAGGACAGTGAT R: CTCCCTCTCTGAGACCTCTTCT</td>
<td>391</td>
<td>59°C</td>
</tr>
</tbody>
</table>

F, forward primer; R, reverse primer; SNP, single nucleotide polymorphism.
reliability of the HRM assay was confirmed by the results obtained from DNA sequencing. The genotype frequencies of all three SNPs (SLC2A9rs11722228, SLC22A12rs893006 and ABCG2rs2231142) were in accordance with the Hardy-Weinberg equilibrium (P=0.73, 0.17 and 0.40, respectively). The T allele of SLC2A9rs11722228 exhibited a frequency of 30.5%, with genotype frequencies of 49.33, 40.33 and 10.33% for CC, CT and TT, respectively. The A allele of SLC22A12rs893006 had a frequency of 23.4%, with genotype frequencies of 57.23, 43.87 and 11.78% for CC, CA and AA, respectively. Additionally, the A allele of ABCG2rs2231142 exhibited a frequency of 33.7%, with genotype frequencies of 44.44, 43.87 and 11.78% for CC, CA and AA, respectively (Table III).

Sub-analysis of SUA levels by genotype. ANOVA was used to evaluate the differences in SUA levels within in each genotype. For SLC2A9rs11722228, the SUA concentration of the
300 patients demonstrated no significant differences among the three genotype groups (411.6 µmol/l for CC, 408.1 µmol/l for CT and 412.6 µmol/l for TT (Fig. 2; P=0.424 vs. CC). For SLC2A9rs11722228, the SUA concentration of male subjects demonstrated no significant differences among the three genotypic groups (449.9 µmol/l for CC, 467.3 µmol/l for CA and 474.5 µmol/l for AA; Fig. 2C, P=0.389 vs. CC).

Age-adjusted OR and 95% CI of hyperuricemia for ABCG2rs2231142 genotypes. An age-adjusted logistic regression analysis was used to verify the association of ABCG2rs2231142 genotypes and hyperuricemia, as presented in Table IV. A total of 100 subjects were randomly selected from the hyperuricemia and normal SUA groups for this analysis.
The results revealed that the CA genotype frequency was 58% in the hyperuricemia group and 46% in the normal SUA group (OR=2.405; *P*=0.036). The AA genotype frequency was 13% in the hyperuricemia group and 8% in the normal SUA group (OR=1.133; *P*=0.043). The A allele of ABCG2rs2231142 exhibited a significant association with an increased risk of hyperuricemia.

Linkage disequilibrium analysis for SLC22A12rs893006 and SLC22A12rs1529909. The present study reported that the SLC22A2rs1529909 mutation (T/C, 146 bp) was always accompanied by the SLC22A12rs893006 mutation when SLC22A12rs893006 was genotyped via HRM curves. Additionally, computational analysis of linkage disequilibrium statistics was performed in the present study using Haploview 4.2 software (17). The results demonstrated that the variants rs893006 and rs1529909 of the SLC22A12 gene were in complete linkage disequilibrium: *R*²>0.8 (Fig. 3).

Discussion

In the present study, the prevalence of hyperuricemia was 32.6% (46.5% in men and 27.7% in women) in the Chinese population of the southeast coastal region, which was notably higher compared with those reported in other regions, including 24.4% in Bangkok (59% in men and 11% in women) (18), 21.4% in the United States (9) and 25.8% in Japan (5). Unexpectedly, the data of the present study revealed that the youngest group (20‑30‑years‑old) exhibited higher mean SUA levels (420.2±104.9 µmol/l) compared with the other age groups (30‑40 years old and 40‑50 years old). This suggested that dietary habits, including high seafood intake, and lifestyle may partly contribute to high SUA levels; however, genetic factors may also serve an important role in affecting SUA levels. In addition, a high incidence of hyperuricemia within the younger ages groups in this region was observed in the present study.
The ABCG2 gene encodes a membrane transporter belonging to the ATP-binding cassette superfamily of membrane transporters, which mediates urate excretion via the proximal renal tubule (19). A meta-analysis of 28,141 European individuals revealed that the gene exhibiting the strongest effects on SUA levels was SLC2A9, and the second was ABCG2 (7). Conversely, a GWAS on the Chinese population suggested that the effects of ABCG2 on SUA levels were stronger compared with SLC2A9 (20). In the present study, the variants of ABCG2rs2231142 were analyzed using PCR-HRM; SUA levels were compared among the three genotype groups. The results of the present study demonstrated that the genotype frequencies of CC, CA and AA were 44.44, 43.87 and 11.78%, respectively, in this region. Furthermore, the present study reported that individuals harboring the AA genotype of ABCG2rs2231142 exhibited significantly higher concentrations of SUA compared with the CA or CC genotypes. It has been reported that different genotypes may affect SUA levels according to sex (12,21). Some variation between the male and female data was demonstrated in the results of the present study; however, such differences were not revealed to be statistically significant. This suggested that the genotype of homozygous mutation may have a closer association with high concentrations of SUA levels compared with the heterozygous and wild-type. ABCG2rs2231142 is prevalent in the majority of populations, with the A allele frequency varying between 1% in African and 29% in Southeast Asian populations (12). The frequency of the A allele in the present study was 33.67%, which was similar to other East Asian regions (40.5% in Taiwan and 31.0% in Japan) (21,22).

The age-adjusted logistic regression analysis between the hyperuricemia and normal groups demonstrated that the A allele may increase susceptibility to hyperuricemia (OR=2.405, 1.133 for CA and AA, respectively). Therefore, it can be suggested that the ABCG2rs2231142 mutation may represent an important factor contributing to the high incidence of hyperuricemia in the region investigated by the present study.

SLC2A9 is located in chromosome 4 and encodes GLUT9, which is responsible for the reabsorption of UA and the exchange of glucose and fructose in the basolateral membranes of renal proximal tubules (23,24). SLC22A12, encoding URAT1, is a member of the organic anion transporter family and primarily regulates the renal tubular reabsorption of UA (10). The present study reported that individuals carrying wild-type alleles in SLC2A9rs11722228 and

Table IV. Age-adjusted OR and 95% CI of hyperuricemia for ABCG2rs2231142 genotypes.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Control</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>CC</td>
<td>14</td>
<td>32</td>
</tr>
<tr>
<td>CA</td>
<td>15</td>
<td>31</td>
</tr>
<tr>
<td>AA</td>
<td>2</td>
<td>6</td>
</tr>
</tbody>
</table>

CI, confidence interval; OR, odds ratio; N/A, not applicable.

Figure 3. Haploview results for SLC22A12rs893006 and SLC22A12rs1529909. (A) Results of sequencing compared with the NCBI database via DNAMAN 8.0 software. (B) Sequencing results matched with those analyzed from high-resolution melting. (C) Linkage disequilibrium analysis via Haploview software (Haploview 4.2). SLC2A9, solute carrier family 2 member 9; SLC22A12, solute carrier family 22 member 12.
SLC22A12rs893006 exhibited higher SUA levels compared with those possessing variant alleles; however, the differences did not reach statistical significance. A larger difference in the mean SUA levels between SLC22A12rs893006 genotypes was detected in males compared with females. Previous studies investigating the American Indian, Japanese and Korean populations have identified variants of SLC2A9 to be principal determinants of SUA levels (22,25,26). In particular, a meta-analysis of European populations demonstrated that the SLC2A9rs734553 polymorphism may be an independent genetic marker associated with SUA levels (7). It has been reported that Japanese population revealed the polymorphism SLC22A12rs893006 to be an independent genetic marker for predicting hyperuricemia (11). Although no significant differences in SUA levels were observed among the genotype groups in the present study, non-significant associations between lower SUA levels with particular genetic variants, such as the A allele in SLC22A12rs893006, were revealed, which was in accordance with the findings of a previous study (9). Minor differences in the data of the present study may be due to differing effects of genetic variants exerted on SUA levels, which may be attributed to various ethnic groups, diet lifestyle and any potential underlying health conditions.

Notably, the present study revealed that the variants rs893006 and rs1529909 of the SLC22A12 gene were in complete linkage disequilibrium; to the best of our knowledge, this has not been reported in previous GWAS. The results of the present study suggested that these two linked loci may possibly encode a particular structure in URAT1 affecting the function of the UA transporter. Further functional investigation is required to confirm the results of the present study and improve understanding of the underlying biological mechanisms of the effects exerted by these polymorphism on URAT1.

However, there were certain limitations to the present study. Firstly, all SNPs that have been confirmed to affect SUA levels were not evaluated in other ethnic groups. Additionally, the present study aimed to investigate the effects of gene mutations on SUA levels; however, lifestyle factors and other parameters of metabolic conditions were not considered. Therefore, further investigation into other functional SNPs and an analysis of the numerous contributing factors in the Chinese population of the southeast coastal region may be conducted in the future.

In conclusion, the present study reported a high incidence rate of hyperuricemia in the Chinese population of the southeast coastal region, which was significantly associated with variants in ABCG2rs2231142; however, further investigation into whether SLC22A9rs11722228 and SLC22A12rs893006 may act as important genetic candidates in the regulation of SUA levels in this region is required.

Acknowledgements
Not applicable.

Funding
The present study was supported by the Department of Education, Guangdong Government Scheme for Research and Control of Infectious Diseases.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
QZ made substantial contributions to the design of the present study, data acquisition, data analysis and reviewed the manuscript. XY made substantial contributions to the design of the present study and contributed to the writing of the manuscript. YX conducted the high-resolution melting methods and analyzed the statistical data. KL collected clinical characteristics of the subjects enrolled in the present study and revised the manuscript for important intellectual content. XJ revised the manuscript for important intellectual content and participated in the design of questionnaire survey. XL and YW drafted the manuscript and participated in all experiments of the present study. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Shantou University Medical College. All participants provided written informed consent.

Patient consent for publication
All participants gave written informed consent including genotyping, and informed consent for the publication of any associated data and accompanying images.

Competing interests
The authors declare that they have no competing interests.

References


